Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant
Source: Streetwise Reports  (7/20/21)
Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets. More >

Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data
Source: Streetwise Reports  (7/19/21)
Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial. More >

Merger of Two Biopharmas 'Brings a New Dawn'
Source: Streetwise Reports  (7/14/21)
The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report. More >

FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design
Source: Streetwise Reports  (7/14/21)
The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report. More >

Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2
Source: Streetwise Reports  (7/12/21)
Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue. More >

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery
Source: Streetwise Reports  (7/9/21)
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke. More >

Biopharma Files New Drug Application for Lead Clinical Product
Source: Streetwise Reports  (7/7/21)
A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report. More >

Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity
Source: Streetwise Reports  (7/7/21)
The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report. More >

Biohaven Posts Revenue of $93 Million in Q2 for Its Migraine Medicine
Source: Streetwise Reports  (7/7/21)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment. More >

ALX Oncology Shares Rise on Positive Response and Survival Data in Phase 1b Gastric Cancer Trial
Source: Streetwise Reports  (7/6/21)
Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer. More >

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases
Source: Streetwise Reports  (7/2/21)
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. More >

Coverage Initiated on Developer of Psychedelic Drugs for PTSD, Smoking Cessation
Source: Streetwise Reports  (6/30/21)
The investment thesis for Mydecine Innovations Group is presented in a ROTH Capital Partners report. More >

Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke
Source: Streetwise Reports  (6/30/21)
Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency. More >

Biotech Takes a 'Disruptive Drug Development Approach' to Destroy Dysregulated Transcription in Cancer
Source: Streetwise Reports  (6/30/21)
Kronos Bio's key assets are reviewed in an H.C. Wainwright & Co. report. More >

Cerevel Shares More Than Double on Positive Topline Results in Phase 1b Schizophrenia Trial
Source: Streetwise Reports  (6/29/21)
Shares of Cerevel Therapeutics hit a new 52-week high after the company released positive topline results for its CVL-231 in a Phase 1b clinical trial in schizophrenia patients. More >

Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial
Source: Streetwise Reports  (6/28/21)
Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis.

More >

Eli Lilly Receives FDA Breakthrough Therapy Designation for Alzheimer's Treatment
Source: Streetwise Reports  (6/24/21)
Eli Lilly and Co's shares traded 8% higher and reached a new 52-week high after the company reported the FDA granted its investigational antibody therapy donanemab Breakthrough Therapy designation for use in treating Alzheimer's disease. More >

Price Target Raised on Biopharma Achieving Positive Atopic Dermatitis Study Results
Source: Streetwise Reports  (6/23/21)
Aclaris Therapeutics' new clinical trial data and a recent financing are discussed in an H.C. Wainwright & Co. report. More >

Biotech Reports Encouraging Efficacy Data in Wet AMD, Target Price Raised 66%
Source: Streetwise Reports  (6/23/21)
These new results, from a Clearside Biomedical trial, are presented and interpreted in a ROTH Capital Partners report. More >

3D Systems and CollPlant Biotech to Create Bioprinted Breast Reconstruction Treatment Solutions
Source: Streetwise Reports  (6/22/21)
3D Systems Corp. shares rose 27% after the company reported it is partnering with CollPlant Biotechnologies to develop bioprinted solutions use to improve breast reconstruction treatments. More >

Anavex Posts Strong Correlated Biomarker Data in Phase 2 Adult Rett Syndrome Trial
Source: Streetwise Reports  (6/21/21)
Anavex Life Sciences shares traded 13% higher after the company reported that ANAVEX®2-73 (blarcamesine) biomarker correlated highly with the predetermined efficacy endpoints in its Phase 2 clinical trial of adult patients with Rett syndrome. More >

Entera Bio Granted Patent for Oral Parathyroid Hormone by EU Patent Authority
Source: Streetwise Reports  (6/17/21)
Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism. More >

Biotech Reports Positive Preclinical COVID-19 Study Results
Source: Streetwise Reports  (6/16/21)
These data and next steps for Novan's antiviral SB019 are provided in a ROTH Capital Partners report. More >

Immuno-oncology Firm Advances Lead Asset in Mesothelioma
Source: Streetwise Reports  (6/16/21)
The status of ONCOS-102 in several of Targovax's development programs is discussed in an H.C. Wainwright & Co. report. More >

Altimmune Posts Positive Interim Weight Loss Results in Phase 1 ALT-801 Trial
Source: Streetwise Reports  (6/16/21)
Altimmune Inc. shares traded 16% higher after the company reported positive interim data from a Phase 1 study of ALT-801 in overweight and obese trial participants. More >